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Urinary LL-6/EGF ratio: A useful prognostic marker for the progression
of renal damage in IgA nephropathy. Interleukin 6 (IL-6) is produced by
human mesangial and tubular cells, and its urinary levels has been
proposed as a marker of mesangial proliferation and tubulointerstitial
damage. Epidermal growth factor (EGF) is expressed within the Henle's
loop and the distal tubule and has been shown to accelerate recovery from
renal injury. In the present study we have defined renal gene and protein
expression of IL-6 and EGF in 10 normal, 10 nonproliferative glomeru-
lonephritis (NPGN) and 30 IgA nephropathy (IgAN) human kidneys by
RT-PCR, in situ hybridization and immunohistochemical techniques.
Moreover, urinary IL-6 and EGF levels were measured in 41 patients with
IgAN and in 20 normal subjects (N). In normal kidneys, EGF was
localized in Henle's loop and distal convoluted tubule whereas IL-6 was
mainly located in the proximal tubule and, less, within the glomerulus. In
IgAN patients, EGF was decreased whereas IL-6 expression was up-
regulated. These modifications paralleled the degree of tubulointerstitial
damage. Moreover, IgAN patients as a whole exhibited a reduction of
EGF and an increase of IL-fl urinary concentration (EGF values: N,
12.96 1.15; IgAN Grades 1—2, 20.05 2.64; Grades 3—4, 7.60 1.70;
Grade 5, 3.14 0.71, ng/mg urinary creatinine. IL-6 values: N, 2.04
0.51; IgAN Grades 1—2, 3.26 0.38; Grades 3—4, 5.67 0.92; Grade 5,
27.20 9.70 pg/mg urinary creatinine), that correlated with the degree of
histological lesions, the presence of hypertension and serum creatinine
level. Interestingly, patients with the highest urinary IL-6/EGF ratio
showed a worse evolution in a three year follow-up. In conclusion, our
data show that: (1) renal IL-6 and EGF expression are strictly correlated
to the degree of tubulointerstitial damage; and (2) urinary IL-6/EGF ratio
might be a valuable prognostic marker for the progression of the renal
damage in IgAN.
IgA nephropathy (IgAN) is a chronic mesangioproliferative
glomerulonephritis (GN) characterized by the predominance of
granular and electron dense deposits of IgA, and frequently, C3 in
the glomerulus [1]. It has a variable course and leads to end-stage
renal disease (ESRD) in a substantial number of cases [1]. Lee,
Rao and Franklin [21 observed that histologic grading at the initial
renal biopsy may be a useful prognostic indicator of the clinical
outcome of IgAN. Indeed, it has been demonstrated that only
patients with moderate to severe histologic lesions develop ESRD
[1,21.
In the recent years several lines of evidence have pointed out
that histopathological changes within the tubulointerstitial com-
partment promote the progression of renal damage, regardless of
its original disease process [reviewed in 3—6]. The extent of the
interstitial infiltrate, which consists largely of T cells and macro-
phages, correlates with the degree of functional impairment and is
a good predictor of long-term prognosis [3].
Several investigations showed that cultured tubular cells syn-
thetize and secrete, both constitutively and inducibly, an array of
peptides which stimulate cell trophism and proliferation (growth
factors), chemoattraction (chemokines), and modulate vessel tone
(vasoactive peptides) [reviewed in 4—9]. Fine, Ong and Torman
[5] hypothesized that protein overload in the glomerular ultrafil-
trate or hypertension-induced microvascular ischemia may cause
tubular injury, which in turn induces an up- or a down-regulation
of the above peptides. Therefore, we decided to focus our
attention on two cytokines, namely interleukin-6 (IL-6) and
epidermal growth factor (EGF), that have been implicated in the
progression of renal damage and in the repair process [10—18].
At the renal level, glomerular mesangial and tubular epithelial
cells express and secrete IL-6 [10, 19, 20]. Mesangial hyperpro-
duction of IL-6, induced by phlogistic stimuli, seems to be
responsible, at least in part, for the proliferative histologic lesions
observed in mesangioproliferative GN [10]. Moreover, an in-
crease in renal IL-6 expression and urine concentration correlate
with mesangial proliferation, tubular atrophy and the intensity of
interstitial cellular infiltrates, thus supporting a role for this
cytokine in the progression of renal damage [10—15].
On the other hand, EGF produced by the ascending portion of
Henle's loop and the distal convoluted tubule is a peptide that
seems to modulate tissue repair [16—18]. A reduction of the renal
EGF expression and its urinary concentration has been reported
during acute tubular injury [21—26]. Finally, a glomerular up-
regulation of EGF-receptor (EGF-R) occurs in human mesangio-
proliferative glomerulonephritis (MPGN), which indirectly sug-
gests a pathogenetic involvement of the EGF/EGF-R loop in
renal damage [27].
In the present study we evaluated the renal gene expression and
protein synthesis of IL-6 and EGF, and measured urinary IL-6
and EGF concentration in a chronic form of GN, namely IgAN.
Furthermore, we correlated renal cytokine expression and urinary
IL-6/EGF ratio with serological (serum creatinine), urinary (pro-
teinuria), and histopathological (glomerular and tubular intersti-
tial damage) findings of this disease.
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Patients
Forty-one patients with biopsy-proven primary IgAN (27 males
and 14 females) gave their informed consent and were enrolled
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into the study. Twenty healthy volunteers and 10 patients affected
by nonproliferative GN (NPGN; 5 minimal change disease, 5
membranous nephropathy) strictly matched for sex and age were
also recruited as controls.
Diagnosis was made by renal biopsy and standard examination
of the cortical tissue by light microscopy and immunofluores-
cence. As routinely performed in our institution, histologic diag-
nosis of IgAN was also supplemented with a grading of disease
severity according to the classification in five classes described by
Lee et a! [2]. Briefly, Grade I showed mild glomerular changes
with occasional slight mesangial thickening (segmental) without
hypercellularity and no tubulointerstitial changes (mild GN). In
Grade II, glomerular changes showing localized mesangial prolif-
eration and sclerosis were found in less than half of the glomeruli.
Small crescents were rarely observed and no tubulointerstitial
changes were present (minor GN). Grade III was characterized by
diffuse mesangial proliferation and thickening of the basal mem-
brane with a focal and segmental distribution. Occasionally, small
crescents and adhesions, as well as tubulointerstitial changes
(focal interstitial edema and infiltrate) were observed. Tubular
atrophy was rare (focal segmental GN). In Grade IV there was a
marked diffuse mesangial proliferation and sclerosis. Crescents
were present in up to 45% of glomeruli. Partial or total glomer-
ulosclerosis was frequent. Tubular atrophy, interstitial inflamma-
tion and occasional interstitial foam cells were frequent findings
(diffuse proliferative GN). Finally, Grade V was similar to Grade
IV but the histologic lesions were more severe. Crescents were
present in more than 45% of glomeruli (diffuse proliferative and
scierosing GN). Conventionally, we defined the Grade 1-Grade 2
(G1-G2) classes as mild and nonprogressive disease, G3-G4 as
moderate and potentially progressive disease, and G5 as severe
and progressive disease.
Urine collection
At the time of biopsy, fresh urine samples were collected in the
morning, centrifuged at 600 x g for five minutes and dialyzed
thrice against sterile PBS for two hours at 4°C. Samples were
harvested from dialysis tubes (MWCO 5,000, Spectrum, Los
Angeles, CA, USA) and frozen at —20°C until tested, Urinary
studies were performed in IgAN patients and normal controls.
None of them had urinary tract infection at the time of the study.
Renal studies
Thirty out of 41 renal biopsies from IgAN patients (13 patients
were in classes G1-G2, 10 patients were grouped in classes G3-G4;
7 patients were in G5 class), 10 renal biopsies from patients
affected by nonproliferative GN, and 10 normal-appearing por-
tions of kidneys removed for renal carcinoma, were adequate for
immunohistochemistry and in situ hybridization. Duplicate mea-
surements of total renal cortex IL-6 mRNA were performed in 20
patients affected by IgAN (7 patients in classes G1-G2; 7 patients
in classes G3-G4; 6 patients in the G5 class), as well as in 10
patients affected by NPGN and 10 normal appearing portion of
kidneys removed for renal carcinoma.
Total RNA extraction
Kidney specimens from percutaneous biopsy or surgical ne-
phrectomy were immediately frozen in liquid nitrogen until used.
After taking cryostat sections for immunohistology and in situ
hybridization studies, frozen renal cortex was lysed in 500 jLl of
guanidine buffer and subsequently homogenized with an Ultra-
Turrax T25 (Janke & Kunkel, Staufen, Germany). Total RNA was
extracted by the single-step method, using phenol and chloroform!
isoamylalcohol as previously described [28], and then analyzed in
denaturing gel of 1% agarose and 2.2 M formaldehyde in lx
MOPS running buffer. All gels were stained with ethidium bro-
mide to visualize 28S and 18S ribosomal RNA bands and to
exclude degradation of RNA. Usually, 3 to 10 .rg of total RNA
were obtained from each biopsy.
RT-PCR assay
One microgram of total RNA was reverse-transcribed into
cDNA and then amplified by using the following set of primers
specific for IL-6, EGF or GAPDH:
IL-6
sense 5'-ATG AAC TCC TFC TCC ACA AGC GC-3'
antisense 5'-GAA GAG CCC TCA GGC TGG ACT G-3'
EGF
sense 5' GAT GGG TAC TGC CTC CAT GAT GG-3'
antisense 5' GCG CAG 'ITC CCA CCA €TF CAG GTC TCG-3'
GAPDH
sense 5'-TGG TAT CGT GGA AGG ACT CAT GAC-3'
antisense 5'-ATF CGT TGT CAT ACC AGG A-3'
Twenty microliters of reverse transcription —reaction mixture
containing I g of total RNA, PCR buffer (10 m Tris-HC1, pH
8.3, 50 mi KC1, 2.5 m'vi MgCI2), 1 mrvi dNTPS, 20 U RNasin, 2.5
/LM oligo (dT) and 100 U Moloney murine leukemia virus
(M-MLV) reverse transcriptase were incubated at 42°C for 30
minutes, heated to 95°C for five minutes, and then quickly chilled
on ice.
PCR was performed at a final concentration of 1 X PCR buffer,
200 ILM dNTPS, 0.15 fLM ofeach primer, 1.25 U of AmpliTaq DNA
polymerase (Perkin Elmer, Roche Molecular System, NJ, USA),
in a total volume of 50 d. The amplification profile involved
denaturation at 95°C for 30 seconds, primer annealing and
extension at 60°C for one minute. For semiquantitative analysis,
aliquots (10 1itl) were taken after different numbers of cycles
(20-30-40) to establish the amplification plateau. Thirty cycles was
found to be the best amplification profile able to recognize
differences between samples. Therefore, all samples were ampli-
fied for 30 cycles and then were electrophoresed in 1.5% agarose
gels in Tris borate!EDTA buffer. Gels were stained with ethidium
bromide and photographed. All signals obtained were normalized
to the mRNA levels of GAPDH, a housekeeping gene, and
expressed as a ratio.
Southern blot analysis
To confirm the specificity of PCR products, 1 d of the
amplified cDNA was electrophoresed on 1.5% agarose gel, blot-
ted onto a nylon membrane (Schleicher & Schuell, Dassel,
Germany) and crosslinked by exposure to UV light. After prehy-
bridization, the filter was hybridized with fluorescein labeled
eDNA probes (ECL Random Prime Labeling System; Amersham,
UK) specific for human IL-6, EGF or GAPDH. Hybridization was
performed at 60°C in 5 X SSC, 0.1% SDS, 5% dextran sulphate
and denatured salmon sperm DNA (100 pg/ml). Thereafter, the
filter was washed once in 1 x SSC, 0.1% SDS and once in 0.5 X
SSC, 0.1% SDS at 60°C for 15 minutes each. Following the
stringency washes, the filter was blocked and incubated with
horseradish peroxidase conjugate anti-fluorescein antibody. The
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blot was then covered with the detection buffer, containing
luminol, and exposed for three minutes to Kodak X-omat X-ray
film. The bands obtained were quantified by densitometric anal-
ysis.
Urinaiy IL-6 and EGF assay
Quantitative determination of the IL-6 and EGF levels in urine
was performed using a human interleukin-6 and a human EGF
ELISA Kit (Biotrak; Amersham), a multiple-sandwich solid-
phase enzyme immunoassay that uses monoclonal and polyclonal
antibodies raised against human IL-6 and EGF proteins. The
enzymatic reaction was detected in an automatic microplate
photometer (Titertek, Flow Labs, USA). The IL-6 and EGF
concentration of the unknown samples were determined by
interpolation into a standard curve developed with known
amounts of purified human IL-6 and EGF proteins, and expressed
in pg/mI. The lower detection limit was 0.7 pglml for IL-6 and 8
pg/ml for EGF. The intra- and interassay coefficients of variation
were 4.2% and 7.0% for IL-6, and 2.9% and 4.1% for EGF,
respectively.
In situ hybridization
Renal tissue was immediately included in OCT compound,
snap-frozen in liquid nitrogen and stored in the same liquid until
used. Frozen sections (6 j.tm thick) were collected onto polylysine-
coated slides, dried briefly on a hot plate at +80°Cand fixed in 4%
paraformaldehyde for 20 minutes. After two washes in PBS,
dehydration in graded ethanols and brief air drying, sections were
immediately used for in situ hybridization. Sections from normal
and diseased kidneys were processed in parallel, using the same
batches of probes and reagents.
For the preparation of RNA probes, the cDNA fragments were
subcloned into the plasmid pGEM1 (Promega Biotech, Florence,
Italy) at the appropriate restriction sites. After linearization of the
plasmids with either HindIII or EcoRI restriction endonuclease,
T7 or SP6 RNA-polymerase (Boehringer Mannheim, Germany),
respectively, were employed to obtain run off transcripts of either
the anti-sense (complementary to mRNA) or sense (anticomple-
mentary to mRNA, negative control) strands. Transcription and
labeling of RNA probes were performed as described [29]. Briefly,
80 Ci of [35S]uridine-5'-(a-thio)-triphosphate (S.A. 1,250 Ci!
mmol; Amersham) was added to a 10 d reaction mixture (0.5 mM
each of adenosine-, cytidine- and guanosine-5'-triphosphate/l ms
dithiothreitol/10 units human placental RNase inhibitor/6 mvi
MgCl2/10 mr'i Tris-HCI, pH 7.5/2 mrvi spermidine/lO mivi NaCI)
including 1 j.tg of linearized plasmid and 16 units of either SP6 or
T7 RNA polymerase. The reaction was allowed to proceed for 60
minutes at 38°C. The DNA plasmid was removed by digestion
with 25 j.g/ml RNase-free DNase I in a mixture containing 12.5
mg/ml of yeast tRNA and 10 units of RNase inhibitor for 10
minutes at 37°C. Free ribonucleotides were removed by phenol-
chloroform extraction followed by ethanol precipitation. To in-
crease the penetration into tissue, the size of the 35S-labeled RNA
probes was adjusted to 50 to 200 bases length by a controlled
alkaline hydrolysis in 80 mi NaHCO3/120 mM Na2CO3, pH
10.2/10 mi dithiothreitol at 60°C. After neutralization in 0.2 M
sodium acetate, pH 6.0/1% acetic acid/lO mrvi dithiothreitol and
ethanol precipitation, RNA probes were stored at —80°C and
used within four weeks. The specific activity usually obtained was
1.2 to 1.4 X i0 cpm/j.tg of 35S-labeled RNA probe.
Prehybridization, hybridization, removal of a nonspecifically
bound probe by RNase A digestion, and further washing proce-
dures were performed for both positive and negative strand RNA
probes as described previously [30, 3fl. Autoradiography was
performed by dipping the dehydrated slides into Ilford G5 nuclear
emulsion (Ilford, Mobberley Cheshire, UK). The exposed slides
were developed using Kodak D19 developer (Kodak, Hemel
Hampstead, UK), counterstained in hematoxylin-eosin and finally
mounted.
Immunohistochemistiy
The immunohistochemical detection of IL-6 and EGF was
performed on frozen kidney sections using chromatographically
purified mouse antibody, specific for human IL-6 (Genzyme,
Cambridge, MA, USA) and human EGF (IgGi, clone 144-8;
Oncogene Science, Inc., Manhasset, NY, USA). Immobilized
mouse antibodies were detected by the immunoalkaline phos-
phatase (APAAP) method with an affinity-purified rabbit anti-
mouse immunoglobulin serum (1:20 dilution; Dako, Milan, Italy)
and APAAP complex (1:50 dilution, Dako), as previously de-
scribed [30, 31]. Alkaline phosphatase was developed with a
mixture of naphtol AS-BI phosphate and new fuchsin (Sigma,
Milan, Italy). Levamisole (Sigma, Munich, Germany) was added
to the development solution in order to block endogenous alka-
line phosphatase activity. Negative controls were performed by
omitting the primary or secondary antibodies, and employing
non-immune mouse serum as first layer. The identification of
tubular segments were performed as follows: (1) for the proximal
tubule, the presence of endogenous alkaline phosphatase was
detected by using a mixture of naphtol AS-BI phosphate and new
fuchsin lacking levamisole, while the CHIP28 antigen, a water
channel protein [321 by an indirect immunofluorescence tech-
nique employing a rabbit polyclonal anti-human CHIP28 antibody
(donated by Dr. G. Valenti) followed by a fluorescein-conjugated
anti-rabbit antibody; (2) for the ascending portion of Henle's loop
and the distal tubule, a direct immunofluorescence technique was
employed using a fluoresceine-conjugate anti-human Tamm-
Horsfall protein (provided by Dr. G.B. Fogazzi) [33].
Microscopy studies
The histologic lesions and the optical density of the signals
generated by the new fuchsin (immunohistochemistry) and silver
grains (in situ hybridization) were quantitated by a computer-
based morphometric analysis system. The video image was gen-
erated with a video camera (Hamamatsu, Milan, Italy) connected
through a frame grabber (Hamamatsu) to a Power PC computer
(Macintosh, Cupertino, CA, USA). Single images were digitized
for image analysis at 256 grey levels. Imported data were analyzed
quantitatively by an Optilab Pro 2.6.1 Software (Graftek, Villan-
terio, PV, Italy) that operated a color-based pitch densitometry.
An optical threshold and filter combination was set to select only
the nuclei, the mesangial matrix, the interstitial infiltrate and
fibrosis, the new fuchsin deposits and silver grains. Two observers
independently assessed morphological changes as well as in situ
hybridization and immunohistochemical signals in a double-blind
protocol, as previously described [31].
Total area, glomerular matrix area, glomerular cellularity,
number of interstitial cell infiltrates, areas of interstitial fibrosis
and number of pixels generated by silver grains (in situ hybrid iza-
tion) and new fuchsin (immunohistochemistry) were quantified in
4'I'...
five to eight randomly selected glomeruli or interstitial areas from
each biopsy. The structures of interest were interactively discrim-
inated by the operators using the cursor and then automatically
measured for total area. The resulting counts divided by the total
area gave the measures desired. Using the Statview II Software
(Brain Power Inc., Calabasas, CA) the single data for each
variable were tabulated and Pearson's correlation coefficient were
computed by linear-least squares regression.
Statistical analysis
Quantitative data were compared among the groups by
ANOVA, and multiple interferences were drawn by Fisher's
protected t-test. The correlation coefficients are Pearson's r
values.
Results
IgAN patients, as a whole, showed an increased expression of
IL-6 niRNA by PCR in total renal cortex compared to normals
and to patients affected by NPGN (Fig. 1). Specifically, the
increase was remarkable only in those biopsies showing relevant
signs of tubulointerstitial damage (tubular atrophy, cellular infil-
trates). Indeed, patients with moderate-severe tubulointerstitial
lesions (G3-G4 and G5 classes) had a 1.76- and 4.24-fold increase
of IL-6 mRNA levels, respectively, compared to normals, whereas
the IL-6/GAPDH ratio of G1-G2 patients did not differ from
normals or from patients affected by NPGN (1.0, 1.3 and 0.90,
respectively; Figs. 1 and 2). It was interesting to observe that the
• only NPGN patient (a case with membranous nephropathy)
• displaying high mRNA levels of IL-6 (Fig. 1) also had severe
tubulointerstitial lesions and showed an unfavorable outcome at
the follow-up.
To characterize the cellular source of IL-6 production, in situ
hybridization coupled to immunohistochemistry were employed.
In normal appearing renal tissue, IL-6 niRNA and protein
expression was faintly observed within some portions of tubules
(Figs. 3 and 4). The IL-6 cRNA antisense probe and anti-IL-6
antibody did not label either the glomerulus or the vascular tree
and the interstitium. By immunohistochemistry, IL-6 was mostly
found intracellularly, with a diffuse intracytoplasmatic pattern. As
demonstrated by endogenous alkaline phosphatase staining, the
tubules expressing IL-6 were of proximal origin, while tubules
positive for the Tamm-Horsfall protein (1-lenle's loop and distal
convoluted tubules) turned out to be negative (data not shown).
IL-6 was up-regulated both at the transcriptional and post-
transcriptional level in diseased kidneys (Figs. 3 and 4). This
increased gene and protein expression was found both at the
tubular as well as at the interstitial level, particularly in areas of
tubulointerstitial damage showing tubular atrophy and interstitial
cellular infiltrates. Moreover, an intense gene and protein expres-
sion was also observed within glomeruli with segmental or diffuse
histologic lesions, whereas IL-6 up-regulation was mainly located
into the mesangial areas. A strict correlation was found between
IL-6 gene and protein expression and the histological features of
the disease (glomerular sclerosis, r = 0.516, P < 0.0005; mesangial
proliferation, r = 0.513, P < 0.0006; tubular atrophy, r = 0.528,
P < 0.0004; interstitial infiltrates, r = 0.530, P < 0.0004).
In NPGN, IL-6 gene and protein expression paralleled the
pattern observed in normal kidneys, except for the patient show-
ing high IL-6 mRNA levels in total cortex (Fig. 1).
N NPGN G1-G2 G3-G4 G5
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Fig. 2. Representative Southern blots of IL-6, EGF and GAPDH specific
PCR amplification products, demonstrating the target gene expression in
noimal (N), mild (G1-G2 classes), moderate (G3-G4 classes) and severe
(G5 class) histologic forms of IgAN.
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Fig. 1. IL-6/GAPDH (A) and EGF/GAPDH (B) ratio in normals, NPGN
and Ig.4 N patients.
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Fig. 3. IL-6 mRNA in a normal appearing kidney and IgAN. Bright (A) and dark (B) field photomicrographs of normal appearing portions of human
kidney reveal positive hybridization for IL-6 in the tubules ('i) (X200; positive hybridization is indicated by collection of black or white grains in the
bright and dark field, respectively). (C and D) Bright and dark field photomicrographs (x200) show an intense signal of hybridization in the tubules ( t)
and the interstitium ( j' ) in a G3 histologic case of IgAN. (E and F) Bright and dark field photomicrographs (x200) show an intense signal of
hybridization in tubules ( ' ), one of which is cystic ( ' 1' ), within the interstitium ('()') and the glomerulus ('ff'fl').
Fifteen out of 41 urine samples of IgAN patients showed IL-6 moderate-severe forms of IgAN, although only patients with G5
levels higher than the normal range (mean 2 SD). All patients histologic grade reached levels statistically different from normals
with NPGN but one displayed normal urinary levels of IL-6. and from patients affected by NPGN (Table 1).
Urinary IL-6 concentrations were higher in patients affected by In normal kidney, EGF gene and protein expression was mainly
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Fig. 4. Immunohistochemistry for IL-6 protein in a normal appeathig kidney and IgAN. (A) Immunostaining of IL-6 protein in normal kidney is seen as
the dark red alkaline phosphatase product within the proximal tubules (t). Immunostaining of IL-6 protein in IgAN with G2 class (B), G4 class (C)
and G5 class (D). In B the pattern of IL-6 immunostaining resembled that observed in A, while a striking increase of IL-6 protein was observed both
in the glomerulus ('if) and in the tubulointerstitial areas (proximal tubules, , and interstitial infiltrate, ' ' ) in C and D. (E) Note the increase of IL-6
protein within tubules with atrophy and necrosis (1' ) as well as in cellular casts ('if). (F) Immunostaining with a nonimmune serum.
distributed in 1-lenle's loop and distal convoluted tubules, and
colocalized with Tamm-Horsfall staining (data not shown), while
the glomerulus, the remaining tubular segments, the interstitum
and the vascular tree were negative (Figs. 5 and 6).
Compared to normals and to patients affected by NPGN but
one, EGF gene and protein expression, as demonstrated by
RT-PCR and in situ hybridization techniques, was down-regulated
in 1gAN patients (Figs. 1, 2, 5 and 6). These modifications
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Fig. 5. EGF mRNA in a normal appearing kidney and IgAN. Bright (A) and dark (B) field photomicrographs of normal appearing portions of kidney
revealing positive hybridization for EGF at the tubular level ( j' ) (200X; positive hybridization is indicated by collection of black or white grains in the
bright and dark field, respectively). (C and D) Bright and dark field photomicrographs (200x) show a down-regulation of EGF mRNA in a G4 class
of IgAN. Note the damaged tubules (1) lacking EGF-exprcssion.
Table 1. IL-6 (pg/mg urinary creatinine) and EGF (nglmg urinary
creatinine) urinary concentration
Normals IgAN G1-2 IgAN G3-4 TgAN G5
EGF 12.96 1.15 20.05 2.64a 7.60 1.70 3.14 0.71
IL-6 2.04 0.51 3.26 0.38 5.67 0.92 27.20 9.70k'
P < 0.00 1 compared to normals
Data are mean SEM.
paralleled the degree of tuhulointerstitial damage (tubular atro-
phy, r = 0.663, P < 0.0001; interstitial infiltrates, r = 0.677, P <
0.0001). Interestingly, the NPGN patient with increased IL-6
expression showed also a low EGF expression. Moreover, while
IgAN patients affected by G1-G2 histological classes showed an
increase in urinary EGF concentration, patients with more severe
histological lesions showed a statistically significant reduction
compared to normals and to patients affected by NPGN (Table 1).
As shown in Table 2, urinary IL-6/EGF ratio allowed to
discriminate patients with progressive disease from those with a
stable clinical course over a 36 month follow-up. Specifically,
patients with a urinary IL-6/EGF ratio higher than I showed a
worse evolution compared to patients with a ratio lower than I
(Fig. 7). Finally, urinary IL-6IEGF ratio correlated with the
histological grading and the presence of hypertension, but not
with proteinuria (Table 3).
Discussion
In the present study, we investigated the pathogenetic involve-
ment of two cytokines, IL-6 and EGF, in a chronic form of
glomerulonephritis, IgAN. IL-6 is a multifunctional cytokine,
produced by a variety of cell types, which is able to exert its effects
on infiltrated inflammatory cells as well as on structural cells in
tissues [34—36]. Besides blood cells (T cells and macrophages),
several normal as well as transformed cells of epithelial origin,
have been reported to produce IL-6 upon appropriate stimulation
in vivo and in vitro [34—36]. Interleukin-6 (IL-6) has been impli-
cated in the injury process [34, 35] as a cytokine able to regulate
the inflammatory and immune reaction and to stimulate prolifer-
ation of a variety of cell types [34—36]. Moreover, an abnormal
expression of IL-6 has been documented in several diseases such
as psoriasis, rheumatoid arthritis, Castleman' disease, AIDS,
alcoholic liver cirrhosis, and cardiac myxoma [37—42].
The kidney represents the main source of EGF, which is chiefly
produced by the ascending portion of Henle's loop and by the
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Fig. 6. Immunohistochemistiy for EGF protein
in a normal appearing kidney and IgAN. (A)
Immunostaining of EUF protein in normal
kidney is seen as the dark red alkaline
phosphatase product within the distal tubules(t) and Henle's loops (1' 1). Immunostaining
of EGF protein in IgAN with G2 class (B) and
G4 class (C). In B, the pattern of EGF
immunostaining resembled that observed in A,
while a striking down-regulation of EGF
protein was observed both in the distal tubules
and in Henle's loops () in C.
distal convoluted tubule, and seems to play an important role in modulation of glomerular hemodynamics, activation of renal
the maintenance of renal tubular trophism and in the recovery metabolism, changes in tubular transport and eicosanoid synthesis
from acute tubular injury [16—18, 43—45]. An array of renal [46—54]. In addition, EGF may direct renal cell proliferation
responses are elicited by systemic administration of EGF such as during fetal life [55]. Although several studies have demonstrated
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Table 2. Urinary IL-6 and EGF concentration, histologic features and clinical follow-up of patients affected by IgA nephropathy
Abbreviations are: TX, transplantation; HD, hemodialysis; P, proteinuria; H, hypertension (1, absent; 2, present). A total of 33 patients concluded
the 36 month follow-up (T36). Three patients were lost at the 12 month follow-up (LF), and the remaining 5 patients are still in the first 12 months of
follow-up.
the pathogenetic involvement of EGF in acute forms of renal
damage [21—25], data regarding its importance in chronic forms
are still lacking.
In agreement with Horii and coworkers and Fukatsu et al
[10—12], we found an increase of renal IL-6 mRNA expression
and urinary IL-6 concentration in patients affected by moderate to
severe histologic forms of IgAN compared to patients with mild
histological lesions, NPGN, and normals. Moreover, to our knowl-
edge we report here, for the first time, that there also is an
increase of IL-6 gene expression. Taken together, these data
suggest that in moderate to severe forms of IgAN an up-
regulation of IL-6 occurs bt)th at the transcriptional and post-
transcriptional level. The increased renal IL-6 mRNA and protein
expression, and the urinary IL-6 concentration correlated with the
degree of the histological lesions, and particularly with the
severity of tubulointerstitial damage (interstitial fibrosis, cellular
infiltrates, and tubular atrophy) and the grade of glomerular
sclerosis. In situ hybridization and immunohistochemistry studies
revealed that IL-6 was expressed and produced by mesangial and
proximal tubular cells, as well as by infiltrating cells (monocytes
and lymphocytes). The latter finding may account for the reported
increase of urinary IL-6 concentration in those forms of renal
tubulointerstitial damage lacking a glomerular involvement, such
as acute renal allograft rejection and acute pyelonephritis [13, 561.
In this setting, it is of note that among patients with NPGN an
increase of rcnal IL-6 expression was observed only in one case
showing a severe tubulointerstitial damage. Similarly, Ohta et al
[13] found high levels of urinary IL-6 in patients affected by
Kawasaki's disease, which is characterized by mesangial hypercel-
lularity associated with an impressive interstitial infiltrate of
lymphocytes and giant mononuclear cells. Moreover, Frank et a!
[20] demonstrated that renal tubular epithelial cells and intersti-
tial fibroblasts from normal and diseased kidneys express specific
IL-6 transcripts. Interestingly, Duncan and Berman [57] and Sato,
IL-6 EGF Serum creatinine
pg/mg/cr TO T36 P HNo. Patients Sex Age
Histologic
grading
IL-6/EGF
ratio ><1000
1 PV M 21 01 4.81 18399.0 0.26 0.80 0.70 0.10 1
2 SV M 33 GI 4.56 12557.0 0.36 1.10 1.20 1.32 1
3 CM M 19 GI 5.00 30204.0 0.17 0.90 1.00 0.88 1
4 SA F 30 Cl 1.98 38102.0 0.05 1.03 0.89 0.14 1
5 CD M 19 01 1.97 16811.0 0.11 1.00 0.98 0.89 1
6 DM M 18 G2 5.37 30380.0 0.18 0.90 1.15 0.22 1
7 PA M 17 02 4.94 17749.0 0.28 0.87 0.90 0.63 1
8 MA F 30 G2 4.98 8453.0 0.59 0.80 0.80 0.30 1
9 DD M 36 02 1.53 10741.0 0.14 1.00 1.01 0.30 1
10 PV M 35 G2 2.75 23778.0 0.12 0.97 0.95 0.30 1
11 DV M 17 G2 2.16 14785.0 0.15 1.00 0.90 0.61 1
12 DC M 21 G2 2.61 26854.0 0.10 1.10 1.10 0.34 1
13 PA M 28 G2 1.89 9628.7 0.20 0.99 0.90 3.90 1
14 LA M 55 G2 1.41 6403.0 0.22 1.00 LF 0.80 1
15 CM F 20 02 2.90 35875.0 0.81 0.70 0.60 0.94 1
16 LG M 45 03 4.46 8683.0 0.51 1.00 LF 0.24 1
17 MM F 20 03 7.82 10420.3 0.75 1.10 1.20 4.29 2
18 DP M 26 03 6.68 11231.0 0.59 0.80 0.80 0.45 1
19 CL F 31 03 1.16 8534.9 0.13 0.69 0.78 0.20 1
20 SO M 34 03 9.20 1330.9 6.91 1.10 LF 0.93 2
21 SV M 59 03 3.34 8631.0 0.39 1.70 1.50 0.34 1
22 LA F 40 G3 5.70 2830.0 2.01 1.09 1.10 0.41 2
23 MC F 22 03 3.44 9531.6 0.36 0.81 0.70 0.62 1
24 LD M 31 G3 10.32 3190.5 3.23 1.30 1.50 1.38 2
25 AL M 46 G3 1.86 28488.5 0.06 1.00 — 1.56 1
26 PV M 28 03 10.96 2113.5 5.19 0.90 1.80 1.39 2
27 DF M 19 04 12.94 2962.0 4.37 1.20 2.50 2.49 2
28 PG M 31 G4 2.48 9458.8 0.26 2.00 — 1.10 2
29 MR F 31 G4 2.71 567.4 4.78 1.00 1.50 1.85 2
30 IL F 22 G4 6.02 2372.5 2.54 1.20 1.10 1.39 2
31 CC F 35 04 1.69 11224.0 0.15 0.77 1.00 1.47 1
32 LA M 38 05 3.00 6014.0 0.50 1.37 1.50 1.10 1
33 MV M 21 05 87.73 695.7 126.10 4.00 8.00 (HD) 3.00 2
34 DF M 42 G5 78.40 3829.2 20.47 1.80 3.7 2.02 2
35 BV M 61 05 16.29 2962.0 5.50 1.80 7.60 5.30 2
36 MD F 15 05 26.72 2012.7 13.28 2.00 8.00 (TX) 2.79 2
37 LL M 23 05 12.42 775.8 16.00 2.00 8.00 (TX) 2.60 2
38 MA F 33 05 9.85 2583.7 3.81 1.40 2.20 1.40 2
39 PD M 49 G5 4.40 2357.3 1.87 4.40 — 3.17 2
40 DO F 18 05 27.06 7826.9 3.45 2.00 — 3.00 2
41 CF F 37 05 6.10 2305.8 2.64 5.30 — 3.06 2
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IL-6/EGF 1
ratio
Serum 0.461c I
creatinine
Hypertension
Histology
0.308"
0358b
0.514'
0.635c
1
0730" 1
Proteinuria 0.274 0.513c 0.610" 0.608"
Ito and Mon [58] described that, upon IL-6 stimulation, intersti-
tial fibroblasts are able to produce extracellular matrix compo-
nents as well as a tissue inhibitor of metalloproteinases. These
studies, coupled to our data, support the hypothesis that the
release of IL-6 by cellular infiltrates (lymphocytes and macro-
phages), renal epithelial cells and interstitial fibroblasts may act,
both in an autocrine and in a paracrine fashion, on renal
fibroblasts stimulating cell proliferation and the production of
collagen, which eventually lead to renal interstitial fibrosis. Addi-
tionally, locally-produced IL-6 may activate the cellular infiltrate,
thus playing an additional role in the induction of injury [121.
In parallel with the up-regulation of IL-6 expression in moder-
ate to severe histological forms of lgAN, we observed, for the first
time, a down-regulation of EGF expression both at the transcrip-
tional and post-transcriptional levels, which strictly correlated
with urinary EGF concentration. Data from experimental models
demonstrate that acute glomerular and tubular injury causes a
transient down-regulation of EGF expression, which thereafter
returns to normal or even supernormal levels in the recovery
phase [21—26]. These last findings may explain the increased
urinary EGF concentration observed in G1-G2 classes of IgAN,
which by definition are mild histological forms of IgAN, and why
these patients do not develop ESRD but are in a "chronic
recovery state." Recently, we were able to reveal, in agreement
with other authors, a dramatic decrease of EGF mRNA and
protein expression as well as of its urinary concentration in
patients with acute tubulointerstitial damage, which supports a
role for the growth factor in the pathogenesis of acute tubuloin-
terstitial injury in humans [24, 25]. The present investigation
expands the role of EGF to the pathogenesis of chronic renal
injury observed in human IgAN. Presently, we cannot distinguish
between a down-regulation of EGF gene expression induced by
chronic tubulointerstitial injury on functional tubular cells and/or
a direct effect of cell loss and tubular atrophy. Nonetheless, we
speculate that the same event, namely chronic ischemic injury or
tubular protein overload, may stimulate IL-6 synthesis while
depressing EGF expression. As a consequence, these variations in
cytokine production would determine an alteration of tubular
epithelial trophism as well as an increase of interstitial fibrosis,
and thus would induce the progression of chronic tubulointersti-
tial damage towards sclerosis.
Urinary concentration of EGF and IL-6 was found to mirror the
modifications of their renal expression and to correlate with the
severity of tubulointerstitial damage. Furthermore, having a uri-
nary IL-6/EGF ratio at the time of renal biopsy permitted us to
discriminate between those patients with a progressive disease
from those with a stable clinical course over a 36 month follow-up.
In conclusion, in the present study we report that chronic
tubulointerstitial damage, as observed in a mesangioproliferative
glomerulonephritis such as IgAN, is accompanied by a decrease of
tubular EGF gene and protein expression and an up-regulation of
IL-6, which strictly correlate with the degree of tubulointerstitial
involvement. Finally, we present evidence that urinary IL-6/EGF
ratio may be, in chronic forms of renal damage, a feasible
prognostic indicator of renal progression towards sclerosis.
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